Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wright, Stephen ^a   Boyd, Mark A ^a,b   Yunihastuti, Evy ^c   Law, Matthew ^a   Sirisanthana, Thira ^d   Hoy, Jennifer ^e,f   Pujari, Sanjay ^g   Lee, Man Po ^h   Petoumenos, Kathy ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e ALFRED HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g Institute of Infectious Diseases   (India)

^h QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; ASIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PACIFIC OCEAN; PATIENT MONITORING; PATIENT SELECTION; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ASIA; AUSTRALIA; DEVELOPING COUNTRIES; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84879531443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064902     Document Type: Article

References (28)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29 doi:10.1016/S0140-6736(03)13802-0.
2. May MT, Sterne JAC, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458 doi:10.1016/S0140-6736(06)69152-6.
3. Fischl MA, Richman DD, Grieco MH, Gottleib MS, Volberding PA, et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317: 185-191 doi:10.1056/NEJM198707233170401.
4. Vella SS, Schwartländer BB, Sow SPS, Eholie SPS, Murphy RLR, (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26: 1231-1241 doi:10.1097/QAD.0b013e32835521a3.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, August 27, 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
6. World Health Organization (2011) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010. Available from http://whqlibdocwhoint/publications/2010/9789241599764_eng pdf[Accessed 9 November 2011]: 1-359.
7. Joint United Nations Programme on HIV/AIDS (2011) HIV in Asia and the Pacific: Getting to Zero: 1-144. Bangkok, 2011. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110826_APGettingToZero_en.pdf.
8. Srikantiah P, Ghidinelli M, Bachani D, Chasombat S, Daoni E, et al. (2010) Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. AIDS 24: S62.
9. Boyd MA, Cooper DA (2012) Optimisation of HIV care and service delivery: doing more with less. Lancet. doi:10.1016/S0140-6736(12)61154-4.
10. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, et al (2012) All-cause mortality in treated HIV-infected adults with CD4> = 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. International Journal of Epidemiology 41: 433-445 doi:10.1093/ije/dyr164.
11. The Antiretroviral Therapy Cohort Collaboration, (2009) Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal of Epidemiology 38: 1624-1633 doi:10.1093/ije/dyp306.
12. McManus H, O'Connor CC, Boyd M, Broom J, Russell D, et al. (2012) Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE 7: e48839 doi:10.1371/journal.pone.0048839.t003.
13. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases 38: 1311.
14. Costagliola DD, Lodwick RR, Ledergerber BB, Torti CC, van Sighem AA, et al. (2012) Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. The Lancet Infectious Diseases 12: 119-127 doi:10.1016/S1473-3099(11)70248-1.
15. Australian HIV Observational Database (2002) Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 3: 28-36.
16. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CKC, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
17. World Bank, editor (n.d.) World Bank GNI per capita Operational. Available: http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls. Accessed 2012 August 29.
18. Fine JP, Gray RJ, (1999) A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 94: 496-509.
19. Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, et al. (2008) Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 22: 2381-2390 doi:10.1097/QAD.0b013e328317a6eb.
20. Walker AS, Gibb DM, (2011) Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis 24: 27-33 doi:10.1097/QCO.0b013e3283423e0e.
21. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, et al. (2008) Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 168: 1910-1918 doi:10.1001/archinternmed.2008.1.
22. Achhra ACA, Zhou JJ, Choi JYJ, Hoy JJ, Zhang FF, et al. (2011) The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD. J Int Assoc Physicians AIDS Care (Chic) 10: 160-170 doi:10.1177/1545109711402213.
23. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, et al. (2009) Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr 50: 513-520.
24. Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, et al. (2009) AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 23: 2323-2336 doi:10.1097/QAD.0b013e328331910c.
25. Oyomopito R, Lee MP, Database TAHO, 21 (2010) Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 11: 519-529 doi:10.1111/j.1468-1293.2010.00822.x.
26. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MWG, et al. (2008) Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 5: e148-e1111 doi:10.1371/journal.pmed.0050148.
27. ART-LINC of IeDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, et al (2009) Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23: 1867-1874 doi:10.1097/QAD.0b013e32832e05b2.
28. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, et al. (2009) Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability. Clinical Infectious Diseases 48: 115-122 doi:10.1086/593312.